An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Journal of Substance Abuse Treatment

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 10742642
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cocaine, dopamine and the endogenous opioid system.

  1996cited by this paper
• Acute administration of buprenorphine in humans: partial agonist and blockade effects.

  1995cited by this paper
• Modulation of morphine-induced sensitization by endogenous kappa opioid systems in the rat.

  1993cited by this paper
• The Fifth Edition of the Addiction Severity Index.

  1992cited by this paper
• A review of the role of anti‐opioid peptides in morphine tolerance and dependence

  1992cited by this paper
• Rationale for maintenance pharmacotherapy of opiate dependence.

  1992cited by this paper
• Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway.

  1992cited by this paper
• Upregulation of the opioid receptor complex by the chronic administration of morphine: a biochemical marker related to the development of tolerance and dependence.

  1991cited by this paper
• Depressive symptoms during buprenorphine treatment of opioid abusers.

  1990cited by this paper
• Regulation of striatonigral prodynorphin peptides by dopaminergic agents.

  1990cited by this paper
• Effects of cocaine on extrapyramidal and limbic dynorphin systems.

  1990cited by this paper
• Evidence that the aversive effects of opioid antagonists and kappa-agonists are centrally mediated.

  1989cited by this paper
• Naltrexone treatment--the problem of patient acceptance.

  1989cited by this paper
• Cocaine selectively increases striatonigral dynorphin levels by a dopaminergic mechanism.

  1989cited by this paper
• Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats.

  1988cited by this paper
• Implications of methadone maintenance for theories of narcotic addiction.

  1988cited by this paper
• Buprenorphine is a potent kappa-opioid receptor antagonist in pigeons and mice.

  1988cited by this paper
• Antipsychotic effect of buprenorphine in schizophrenia.

  1987cited by this paper
• Buprenorphine has potent kappa opioid receptor antagonist activity.

  1987cited by this paper
• Human psychopharmacology of ketocyclazocine as compared with cyclazocine, morphine and placebo.

  1986cited by this paper
• Psychotomimesis mediated by kappa opiate receptors

  1986cited by this paper
• Review of naltrexone, a long-acting opiate antagonist.

  1984cited by this paper
• POSSIBLE ANTIDEPRESSIVE EFFECTS OF OPIOIDS: ACTION OF BUPRENORPHINE

  1982cited by this paper
• Dynorphin is a specific endogenous ligand of the kappa opioid receptor.

  1982cited by this paper
• Evidence for an endorphin dysfunction in methadone addicts: lack of ACTH response to naloxone.

  1981cited by this paper
• AGONIST AND ANTAGONIST PROPERTIES OF BUPRENORPHINE, A NEW ANTINOCICEPTIVE AGENT

  1977cited by this paper
• The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory.

  1974cited by this paper
• An inventory for measuring depression.

  1961cited by this paper

• Novel dual kappa/mu opioid ligands based on a tetrahydroisoquinoline-valine hybrid nucleus

  2025cites this paper
• Salvinorin A and Salvia divinorum: Toxicology, Pharmacological Profile, and Therapeutic Potential

  2025cites this paper
• The role of attachment and personality traits in choosing opiate addiction replacement therapy

  2024cites this paper
• The Association Between Self-Reported Anxiety and Retention in Opioid Agonist Therapy: Findings From a Canadian Pragmatic Trial

  2023cites this paper
• Buprenorphine reduces somatic withdrawal in a mouse model of early-life morphine exposure.

  2023cites this paper
• Innovating for real-world care: A systematic review of interventions to improve post-detoxification outcomes for opioid use disorder.

  2022cites this paper
• 'Not at all what I had expected': Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study.

  2021cites this paper
• Peptide Kappa Opioid Receptor Ligands and Their Potential for Drug Development.

  2021cites this paper
• Deciphering the molecular basis of the kappa opioid receptor selectivity: A Molecular Dynamics study.

  2021cites this paper
• Qualitative characterizations of misinformed disclosure reactions to medications for opioid use disorders and their consequences.

  2021cites this paper
• Scoping review of intervention studies to improve opioid and alcohol use outcomes and links to care following inpatient detoxification

  2021cites this paper
• Buprenorphine buccal film for chronic pain management.

  2020cites this paper
• A Narrative Pharmacological Review of Buprenorphine: A Unique Opioid for the Treatment of Chronic Pain

  2020cites this paper
• Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date

  2020cites this paper
• OREX-1019: A Novel Treatment of Opioid Use Disorder and Relapse Prevention

  2019cites this paper
• The optimization of methadone dosing whilst treating with rifampicin: A pharmacokinetic modeling study.

  2019cites this paper
• Safety And Efficacy Of The Unique Opioid Buprenorphine For The Treatment Of Chronic Pain

  2019cites this paper
• The effectiveness of different singly administered high doses of buprenorphine in reducing suicidal ideation in acutely depressed people with co-morbid opiate dependence: a randomized, double-blind, clinical trial

  2018cites this paper
• Fast Effect of Buprenorphine on Opioid-dependent Patients Committed to Suicide : A Double-blind , Randomized , Clinical Trial

  2018cites this paper
• Design, synthesis, and opioid activity of arodyn analogs cyclized by ring-closing metathesis involving Tyr(allyl).

  2018cites this paper
• Antidepressant‐like effects of BU10119, a novel buprenorphine analogue with mixed κ/μ receptor antagonist properties, in mice

  2018cites this paper
• Antidepressant-like effects of BU10119, a novel buprenorphine analogue with mixed kappa/mu opioid receptor antagonist properties, in mice

  2017cites this paper
• Selective kappa opioid antagonists for treatment of addiction, are we there yet?

  2017cites this paper
• Drug Use And Opioid Substitution Treatment In Pregnancy: Evidence From Electronic Health Records

  2017influential citation
• Perioperative Pain Management in Patients on Opioid Replacement Therapy: An Integrative Review

  2017cites this paper
• Cytotoxic Effects of Salvinorin A, A Major Constituent of Salvia divinorum.

  2016cites this paper
• Naltrexone alters the processing of social and emotional stimuli in healthy adults

  2016cites this paper
• Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study.

  2016cites this paper
• Dynorphin A analogs for the treatment of chronic neuropathic pain.

  2016cites this paper
• Mediation of buprenorphine analgesia by a combination of traditional and truncated mu opioid receptor splice variants

  2016cites this paper
• Kappa‐Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials

  2016cites this paper
• Total Synthesis of (-)-Salvinorin A.

  2016cites this paper
• Structure-Activity Relationships of the Peptide Kappa Opioid Receptor Antagonist Zyklophin.

  2015cites this paper
• C7β-Methyl Analogues of the Orvinols: The Discovery of Kappa Opioid Antagonists with Nociceptin/Orphanin FQ Peptide (NOP) Receptor Partial Agonism and Low, or Zero, Efficacy at Mu Opioid Receptors

  2015cites this paper
• Synthesis and characterization of a dual kappa-delta opioid receptor agonist analgesic blocking cocaine reward behavior.

  2015cites this paper
• New developments in the management of opioid dependence: focus on sublingual buprenorphine–naloxone

  2015cites this paper
• Sex Differences in Kappa Opioid Receptor Function and Their Potential Impact on Addiction

  2015cites this paper
• Alanine analogues of [D‐Trp]CJ‐15,208: novel opioid activity profiles and prevention of drug‐ and stress‐induced reinstatement of cocaine‐seeking behaviour

  2014cites this paper
• Prescription Opioid Analgesics Increase Risk of Major Depression: New Evidence, Plausible Neurobiological Mechanisms and Management to Achieve Depression Prophylaxis.

  2014cites this paper
• Evaluation of Opioid Modulation in Major Depressive Disorder

  2014cites this paper
• A non‐rewarding, non‐aversive buprenorphine/naltrexone combination attenuates drug‐primed reinstatement to cocaine and morphine in rats in a conditioned place preference paradigm

  2014cites this paper
• Opus: University of Bath Online Publication Store Open Peer Review

  2014cites this paper
• Association between gene variants and response to buprenorphine maintenance treatment.

  2014cites this paper
• Novel approaches for the treatment of psychostimulant and opioid abuse – focus on opioid receptor-based therapies

  2014cites this paper
• Mixed κ/μ partial opioid agonists as potential treatments for cocaine dependence.

  2014cites this paper
• The effect of opioids on emotional reactivity.

  2013cites this paper
• The macrocyclic tetrapeptide [D‐Trp]CJ‐15,208 produces short‐acting κ opioid receptor antagonism in the CNS after oral administration

  2013cites this paper
• In vivo and in vitro characterization of naltrindole-derived ligands at the κ-opioid receptor

  2013cites this paper
• Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology.

  2013cites this paper
• Development of κ opioid receptor antagonists.

  2013cites this paper
• Opus: University of Bath Online Publication Store

  2013cites this paper
• Physical Presence of Nor-Binaltorphimine in Mouse Brain over 21 Days after a Single Administration Corresponds to Its Long-Lasting Antagonistic Effect on κ-Opioid Receptors

  2013cites this paper
• Synthesis and biological evaluation of dynorphin analogs and, Caco-2 permeability of opioid macrocyclic tetrapeptides

  2013cites this paper
• Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humans.

  2012cites this paper
• La comorbidité entre dépendance aux opiacés et dépression : mécanismes sérotoninergiques dans un modèle murin

  2012cites this paper
• Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.

  2012cites this paper
• Buprenorphine vs methadone treatment: A review of evidence in both developed and developing worlds

  2012cites this paper
• Advances in opioid antagonist treatment for opioid addiction.

  2012cites this paper
• Transdermal delivery of a buprenorphine/naltrexone combination for the treatment of polydrug abuse

  2011influential citation
• Neuropharmacology of the Naturally Occurring κ-Opioid Hallucinogen Salvinorin A

  2011influential citation
• Unexpected Opioid Activity Profiles of Analogues of the Novel Peptide Kappa Opioid Receptor Ligand CJ‐15,208

  2011cites this paper
• Pharmacological enhancement of naltrexone treatment for opioid dependence : a review

  2011cites this paper
• Pharmacological enhancement of naltrexone treatment for opioid dependence: a review

  2011cites this paper
• Deletion of Ac‐NMePhe1 from [NMePhe1]arodyn under acidic conditions, part 2: Effects of cleavage conditions and N‐terminal functionality

  2011cites this paper
• Deletion of Ac‐NMePhe1 from [NMePhe1]arodyn under acidic conditions, part 2: Effects of substitutions on pharmacological activity

  2011cites this paper
• The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors.

  2010cites this paper
• Agonist-antagonist combinations in opioid dependence: a translational approach.

  2010influential citation
• Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action

  2009cites this paper
• The kappa-opiate receptor impacts the pathophysiology and behavior of substance use.

  2009cites this paper
• Peptide Kappa Opioid Receptor Ligands: Potential for Drug Development

  2009cites this paper
• Effects of intravenous patient-controlled analgesia with buprenorphine and morphine alone and in combination during the first 12 postoperative hours: a randomized, double-blind, four-arm trial in adults undergoing abdominal surgery.

  2009cites this paper
• Synthesis of cyclic tetrapeptide CJ 15,208: a novel kappa opioid receptor antagonist.

  2009cites this paper
• Design and synthesis of cyclic arodyn analogues by ring-closing metathesis (RCM) for kappa opioid receptor (KOP) antagonists.

  2009cites this paper
• The effects of C-terminal modifications on the opioid activity of [N-benzylTyr(1)]dynorphin A-(1-11) analogues.

  2009cites this paper
• Potential of Buprenorphine/Naltrexone in Treating Polydrug Addiction and Co‐occurring Psychiatric Disorders

  2008cites this paper
• List of Tables vi List of Figures viii List of Abbreviations ix

  2008cites this paper
• Buprenorphine-induced Symptomatic Hypogonadism in Men: Case Reports and Discussion.

  2008cites this paper
• Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.

  2007cites this paper
• Experimentally induced aggressiveness in heroin-dependent patients treated with buprenorphine: comparison of patients receiving methadone and healthy subjects.

  2007cites this paper
• La Buprenorfina come psicofarmaco

  2006cites this paper
• Depressive-Like Effects of the κ-Opioid Receptor Agonist Salvinorin A on Behavior and Neurochemistry in Rats

  2006cites this paper
• Buprenorphine treatment outcome in dually diagnosed heroin dependent patients: A retrospective study.

  2006cites this paper
• Effectiveness of buprenorphine in double diagnosed patients . Buprenorphine as psychothropic drug

  2006cites this paper
• Naltrexone and buprenorphine combination in the treatment of opioid dependence

  2006cites this paper
• Impaired decision-making in opiate-dependent subjects: effect of pharmacological therapies.

  2006cites this paper
• EFFECTS OF JOINT COCAINE AND ETHANOL ON THE BRAIN OPIOID SYSTEMS

  2005cites this paper
• Structure-activity relationships of arodyn, a novel acetylated kappa opioid receptor antagonist.

  2005cites this paper
• [Nalpha-benzylTyr1,cyclo(D-Asp5,Dap8)]- dynorphin A-(1-11)NH2 cyclized in the "address" domain is a novel kappa-opioid receptor antagonist.

  2005cites this paper
• Effects of JDTic, a selective kappa-opioid receptor antagonist, on the development and expression of physical dependence on morphine using a rat continuous-infusion model.

  2005cites this paper
• Opioids and addiction: Emerging pharmaceutical strategies for reducing reward and opponent processes

  2005influential citation
• Factors associated with the transition from abuse to dependence among substance abusers: implications for a measure of addictive liability.

  2005cites this paper
• A randomized control trial of group counseling in a naltrexone treatment program.

  2004cites this paper
• Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome.

  2004cites this paper
• Practical Considerations for the Clinical Use of Buprenorphine

  2004cites this paper
• Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist.

  2004cites this paper
• Synthesis of novel basic head-to-side-chain cyclic dynorphin A analogs: strategies and side reactions.

  2003cites this paper
• A novel N-terminal cyclic dynorphin A analogue cyclo(N,5)[Trp(3),Trp(4),Glu(5)] dynorphin A-(1-11)NH(2) that lacks the basic N-terminus.

  2003cites this paper
• [Pharmacological treatment of substance dependence from a neuroscientific perspective (I): opiates and cocaine].

  2003cites this paper
• Enhanced humoral response in kappa-opioid receptor knockout mice.

  2003cites this paper
• Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.

  2002cites this paper